PMID- 32320211
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20230829
IS  - 1948-7193 (Electronic)
IS  - 1948-7193 (Linking)
VI  - 11
IP  - 9
DP  - 2020 May 6
TI  - Neurological Insights of COVID-19 Pandemic.
PG  - 1206-1209
LID - 10.1021/acschemneuro.0c00201 [doi]
AB  - The novel coronavirus SARS-CoV-2, which was identified after a recent outbreak in 
      Wuhan, China, in December 2019, has kept the whole world in tenterhooks due to 
      its severe life-threatening nature of the infection. The virus is unlike its 
      previous counterparts, SARS-CoV and MERS-CoV, or anything the world has 
      encountered before both in terms of virulence and severity of the infection. If 
      scientific reports relevant to the SARS-CoV-2 virus are noted, it can be seen 
      that the virus owes much of its killer properties to its unique structure that 
      has a stronger binding affinity with the human angiotensin-converting enzyme 2 
      (hACE2) protein, which the viruses utilize as an entry point to gain accesses to 
      its hosts. Recent reports suggest that it is not just the lung that the virus may 
      be targeting; the human brain may soon emerge as the new abode of the virus. 
      Already instances of patients with COVID-19 have been reported with mild (anosmia 
      and ageusia) to severe (encephalopathy) neurological manifestations, and if that 
      is so, then it gives us more reasons to be frightened of this killer virus. 
      Keeping in mind that the situation does not worsen from here, immediate awareness 
      and more thorough research regarding the neuroinvasive nature of the virus is the 
      immediate need of the hour. Scientists globally also need to up their game to 
      design more specific therapeutic strategies with the available information to 
      counteract the pandemic. In this Viewpoint, we provide a brief outline of the 
      currently known neurological manifestations of COVID-19 and discuss some probable 
      ways to design therapeutic strategies to overcome the present global crisis.
FAU - Das, Gaurav
AU  - Das G
AUID- ORCID: 0000-0002-8432-5384
AD  - Organic and Medicinal Chemistry and Structural Biology and Bioinformatics 
      Division, CSIR-Indian Institute of Chemical Biology, 4, Raja S. C. Mullick Road, 
      Jadavpur, Kolkata, 700 032 WB India.
AD  - Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
FAU - Mukherjee, Nabanita
AU  - Mukherjee N
AUID- ORCID: 0000-0002-0228-5148
AD  - Department of Bioscience & Bioengineering, Indian Institute of Technology 
      Jodhpur, NH 65, Surpura Bypass Road, Karwar, Jodhpur, Rajasthan 342037, India.
FAU - Ghosh, Surajit
AU  - Ghosh S
AUID- ORCID: 0000-0002-8203-8613
AD  - Department of Bioscience & Bioengineering, Indian Institute of Technology 
      Jodhpur, NH 65, Surpura Bypass Road, Karwar, Jodhpur, Rajasthan 342037, India.
AD  - Organic and Medicinal Chemistry and Structural Biology and Bioinformatics 
      Division, CSIR-Indian Institute of Chemical Biology, 4, Raja S. C. Mullick Road, 
      Jadavpur, Kolkata, 700 032 WB India.
AD  - Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - United States
TA  - ACS Chem Neurosci
JT  - ACS chemical neuroscience
JID - 101525337
RN  - 0 (BCG Vaccine)
RN  - 0 (Cytokines)
RN  - 0 (MIRN27 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Receptors, Nicotinic)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (spike protein, SARS-CoV-2)
RN  - EC 3.4.15.1 (Peptidyl-Dipeptidase A)
RN  - EC 3.4.17.23 (ACE2 protein, human)
RN  - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.- (TMPRSS2 protein, human)
SB  - IM
MH  - Aged
MH  - Ageusia/virology
MH  - Angiotensin-Converting Enzyme 2
MH  - Autopsy
MH  - BCG Vaccine/administration & dosage/immunology
MH  - Betacoronavirus/chemistry/metabolism/*pathogenicity
MH  - Brain/pathology/physiopathology/*virology
MH  - Brain Diseases/immunology/pathology/virology
MH  - COVID-19
MH  - Coronavirus Infections/diagnosis/*physiopathology/transmission/virology
MH  - Cytokines/immunology
MH  - Humans
MH  - Inflammation/immunology/pathology/virology
MH  - MicroRNAs/genetics
MH  - Olfaction Disorders/virology
MH  - Olfactory Mucosa/pathology/physiopathology/virology
MH  - Pandemics
MH  - Peptidyl-Dipeptidase A/genetics/metabolism
MH  - Pneumonia, 
      Viral/diagnosis/immunology/pathology/*physiopathology/transmission/virology
MH  - RNA Interference
MH  - Receptors, Nicotinic/metabolism
MH  - SARS-CoV-2
MH  - Serine Endopeptidases/metabolism
MH  - Smoking/metabolism/pathology
MH  - Spike Glycoprotein, Coronavirus/chemistry/genetics/metabolism
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - encephalopathy
OT  - hACE2
OT  - neuroinvasive property
OT  - therapeutic intervention
EDAT- 2020/04/23 06:00
MHDA- 2020/05/12 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1021/acschemneuro.0c00201 [doi]
PST - ppublish
SO  - ACS Chem Neurosci. 2020 May 6;11(9):1206-1209. doi: 10.1021/acschemneuro.0c00201. 
      Epub 2020 Apr 22.